Abstract 436P
Background
With the advent of personalized medicine, recent clinical trials have placed much emphasis on the OS and PFS of cancer patients. However, several international guidelines also emphasize the need for assessing the Health Related Quality of Life (HRQoL) as part of our holistic approach in the management of cancer patients. This study evaluated the present status of the Filipino oncologists’ approach in assessing the quality of life of cancer patients.
Methods
This was a cross-sectional study that utilized a survey questionnaire. Participants included physicians in the care of the cancer patient (consultants & trainees) – medical, surgical, radiation, gynecologic oncologists, and hematologists, who were contacted via email through the database of their respective societies, and personally during scientific meetings / conferences. Descriptive and multivariate analysis were used to analyze the data.
Results
312 oncologists participated. 96% reported that HQRoL assessment was important for clinical work, however 58% perceived HRQoL to be a vague term; 69% agreed that verbal HRQoL assessments were generally enough, and 39% reported that their patients did not accept HRQoL questionnaires. Furthermore, 78% did not know which HRQoL assessment tool to use, and that the questionnaires were too extensive and too lengthy for routine use; 55% reported that they did not feel sufficiently trained to assess HRQoL. About 89.42% reported that they will be more confident if local HRQoL assessment guidelines will be present, and 92.95% agreed to the use of a unified HRQoL assessment tool for Filipino cancer patients.
Conclusions
Filipino oncologists perceived HRQoL patient assessments to be important in clinical practice. However, majority did not know which tool to use and did not feel sufficiently trained to assess HRQoL. The creation of a practice guideline that would facilitate the use of a unified HRQoL assessment tool (containing 5-15 questions) for Filipino cancer patients will be explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract